Aclarion, Inc. (NASDAQ: ACON, ACONW) announced that its board of directors has adopted a limited duration stockholder rights plan effective immediately through March 18, 2027.

The rights plan distributes one preferred stock purchase right for each share of common stock and each rights-eligible warrant outstanding as of March 30, 2026. Each right allows holders to purchase one one-thousandth of a share of Series D Junior Participating Preferred Stock at $14.00 per right.

The rights become exercisable if any person or group acquires beneficial ownership of 10% or more of the company's common stock in a transaction not approved by the board. Existing shareholders who already own 10% or more before the plan's announcement are grandfathered but cannot increase their holdings without triggering the plan.

If triggered, each right entitles holders to receive common stock with market value equal to twice the exercise price, except for the acquiring party whose rights become void. In a merger or similar transaction, rights holders would receive shares of the acquiring company's common stock with equivalent value.

The board may redeem the rights at $0.001 per right or exchange them for common stock at a one-to-one ratio. The plan expires on March 18, 2027, unless earlier redeemed, exchanged, or terminated upon closing of a board-approved merger or acquisition.

Aclarion stated the plan was not adopted in response to any specific acquisition proposal and is intended to ensure all stockholders realize long-term value while giving the board time to evaluate potential offers.

The healthcare technology company develops magnetic resonance spectroscopy solutions for clinical treatments, with its Nociscan platform targeting chronic low back pain diagnosis.